



Universiteit
Leiden
The Netherlands

Human papillomavirus clade A9 specific cellular immunity during the natural course of disease

Hende, M. van den

Citation

Hende, M. van den. (2012, May 31). *Human papillomavirus clade A9 specific cellular immunity during the natural course of disease*. Retrieved from <https://hdl.handle.net/1887/19037>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/19037>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/19037> holds various files of this Leiden University dissertation.

Author: Hende, Muriel van den

Title: Human papillomavirus clade A9 specific cellular immunity during the natural course of disease

Date: 2012-05-31



Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

- Adurthi S, Krishna S, Mukherjee G, Bafna UD, Devi U and Jayshree RS. Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. *Am.J.Reprod.Immunol.* **2008**; 60:55-65.
- Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. *J.Natl.Cancer Inst.* **2004**; 96:1070-1076.
- Akcaay A, Erdem Y, Altun B, Usalan C, Agca E, Yasavul U et al. The booster phenomenon in 2-step tuberculin skin testing of patients receiving long-term hemodialysis. *Am.J.Infect.Control* **2003**; 31:371-374.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* **1997**; 25:3389-3402.
- Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA and Bird CC. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. *Br.J.Cancer* **1997**; 75:722-728.
- Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. *Clin.Cancer Res.* **2003**; 9:5205-5213.
- Baseman JG and Koutsky LA. The epidemiology of human papillomavirus infections. *J.Clin.Virol.* **2005**; 32 Suppl 1:S16-S24.
- Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. *J.Clin.Virol.* **2005**; 32 Suppl 1:S1-S6.
- Bhat P, Mattarollo SR, Gosmann C, Frazer IH and Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. *Immunol.Rev.* **2011**; 239:85-98.
- Black CA. Delayed type hypersensitivity: current theories with an historic perspective. *Dermatol. Online.J.* **1999**; 5:7.
- Bonanni P, Boccalini S and Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. *Vaccine* **2009**; 27 Suppl 1:A46-A53.
- Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. *J.Gen.Virol.* **1999**; 80 (Pt 2):409-417.
- Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. *Int.J.Cancer* **2000**; 88:92-98.
- Bosch FX, Lorincz A, Munoz N, Meijer CJ and Shah KV. The causal relation between human papillomavirus and cervical cancer. *J.Clin.Pathol.* **2002**; 55:244-265.
- Bourgault V, I, Moyal BM, Ziol M, Chaboissier A, Barget N, Berville S et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. *Cancer Res.* **2004**; 64:8761-8766.

- Brandsma JL, Shlyankevich M, Zhang L, Slade MD, Goodwin EC, Peh W et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. *J.Virol.* **2004**; 78:116-123.
- Brandsma JL, Shlyankevich M, Su Y, Roberts A, Rose JK, Zelterman D et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. *J.Virol.* **2007**; 81:5749-5758.
- Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. *Cancer Immunol.Immunother.* **2008**; 57:289-302.
- Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. *J.Infect.Dis.* **2005**; 191:182-192.
- Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26 years. *J.Infect.Dis.* **2009**; 199:926-935.
- Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. *Sex Transm.Dis.* **1996**; 23:333-341.
- Campion MJ, McCance DJ, Cuzick J and Singer A. Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. *Lancet* **1986**; 2:237-240.
- Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Follen M and MacAulay C. Natural history of cervical intraepithelial neoplasia: a meta-analysis. *Acta Cytol.* **2005**; 49:405-415.
- Cardin RD, Brooks JW, Sarawar SR and Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. *J.Exp.Med.* **1996**; 184:863-871.
- Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. *J.Infect.Dis.* **1996**; 174:927-936.
- Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. *J.Infect.Dis.* **2000**; 181:1911-1919.
- Castle PE, Wheeler CM, Solomon D, Schiffman M and Peyton CL. Interlaboratory reliability of Hybrid Capture 2. *Am.J.Clin.Pathol.* **2004**; 122:238-245.
- Centers for Disease and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. *Morb.Mortal.Wkly.Rep.* **2010**; 59:1018-1023.
- Centers for Disease and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. *Morb.Mortal.Wkly.Rep.* **2011**; 60:1117-1123.
- Chambers MA, Stacey SN, Arrand JR and Stanley MA. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. *J.Gen.Virol.* **1994**; 75 (Pt 1):165-169.
- Chan SY, Delius H, Halpern AL and Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. *J.Virol.* **1995**; 69:3074-3083.

- Charo RA. Politics, parents, and prophylaxis--mandating HPV vaccination in the United States. *N.Engl.J.Med.* **2007**; 356:1905-1908.
- Cirisano FD. Management of pre-invasive disease of the cervix. *Semin.Surg.Oncol.* **1999**; 16:222-227.
- Clifford GM, Smith JS, Aguado T and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. *Br.J.Cancer* **2003**; 89:101-105.
- Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. *Lancet* **2005**; 366:991-998.
- Clifford G, Franceschi S, Diaz M, Munoz N and Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* **2006**; 24 Suppl 3:S3-26-S3/34.
- Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M et al. Immunological events in regressing genital warts. *Am.J.Clin.Pathol.* **1994**; 102:768-774.
- Cuschieri KS, Graham C, Moore C and Cubie HA. Human Papillomavirus testing for the management of low-grade cervical abnormalities in the UK--Influence of age and testing strategy. *J.Clin.Virol.* **2007**; 38:14-18.
- Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. *Vaccine* **2008**; 26 Suppl 10:K29-K41.
- Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. *Br.J.Cancer* **2010**; 102:1129-1136.
- Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nat.Med.* **2007**; 13:843-850.
- Daud II, Scott ME, Ma Y, Shiboski S, Farhat S and Moscicki AB. Association between toll-like receptor expression and human papillomavirus type 16 persistence. *Int.J.Cancer* **2011**; 128:879-886.
- de Gruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, Doekhie FS, Remmink AJ et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. *Cancer Res.* **1998**; 58:1700-1706.
- de Hoogh P, Oomen P and Zonnenberg I. Opkomst HPV-vaccinaties per 15 juli 2011, geboortecohorten 1997 en 1998. RIVM **2011**.
- de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. *Cancer Res.* **2002a**; 62:472-479.
- de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. *Vaccine* **2002b**; 20:3456-3464.
- de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. *Cancer Res.* **2004**; 64:5449-5455.

- de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P et al. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. *Int.J.Cancer* **2005**; 114:274-282.
- de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect.Dis.* **2007**; 7:453-459.
- de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol.* **2010**; 11:1048-1056.
- de Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H. Classification of papillomaviruses. *Virology* **2004**; 324:17-27.
- de Vos van Steenwijk PJ, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, Hellebrekers BW et al. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. *Clin.Cancer Res.* **2008**; 14:7188-7195.
- de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhoebe TH, Lowik MJ, van der Hulst JM, Goedemans R et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. *Cancer Res.* **2010**; 70:2707-2717.
- De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM and Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int.J.Cancer* **2009**; 124:1626-1636.
- Denny L, Kuhn L, De SM, Pollack AE, Dupree W and Wright TC, Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. *JAMA* **2005**; 294:2173-2181.
- Denny L, Kuhn L, Hu CC, Tsai WY and Wright TC, Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. *J.Natl.Cancer Inst.* **2010**; 102:1557-1567.
- Dillner J. The serological response to papillomaviruses. *Semin.Cancer Biol.* **1999**; 9:423-430.
- Dillner J. Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. *J.Clin.Virol.* **2000**; 19:7-23.
- Doorbar J. The papillomavirus life cycle. *J.Clin.Virol.* **2005**; 32 Suppl 1:S7-15.
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. *Clin.Sci.(Lond)* **2006**; 110:525-541.
- Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS et al. Prevalence of HPV infection among females in the United States. *JAMA* **2007**; 297:813-819.
- Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. *Eur.J.Immunol.* **2008**; 38:350-363.
- Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepf F et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. *Hum.Vaccin.* **2009a**; 5:705-719.
- Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. *Lancet Infect.Dis.* **2009b**; 9:347-356.

- Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E et al. Human papillomavirus infection is transient in young women: a population-based cohort study. *J.Infect.Dis.* **1995**; 171:1026-1030.
- Evans M and Powell NG. The changing aetiology of head and neck cancer: the role of human papillomavirus. *Clin.Oncol.(R.Coll.Radiol.)* **2010**; 22:538-546.
- Fakhry C, D'souza G, Sugar E, Weber K, Goshu E, Minkoff H et al. Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. *J.Clin.Microbiol.* **2006**; 44:4479-4485.
- Farhat S, Nakagawa M and Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. *Int.J.Gynecol.Cancer* **2009**; 19:508-512.
- Fausch SC, Fahey LM, Da Silva DM and Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. *J.Immunol.* **2005**; 174:7172-7178.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int.J.Cancer* **2010**; 127:2893-2917.
- Franken KL, Hiemstra HS, van Meijgaarden KE, Subronto Y, den HJ, Ottenhoff TH et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. *Protein Expr.Purif.* **2000**; 18:95-99.
- Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. *Nat.Rev.Immunol.* **2004**; 4:46-54.
- Frazer IH, Leggatt GR and Mattarollo SR. Prevention and treatment of papillomavirus-related cancers through immunization. *Annu.Rev.Immunol.* **2011**; 29:111-138.
- Garland SM. Imiquimod. *Curr.Opin.Infect.Dis.* **2003**; 16:85-89.
- Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A et al. Improved amplification of genital human papillomaviruses. *J.Clin.Microbiol.* **2000**; 38:357-361.
- Han R, Reed CA, Cladel NM and Christensen ND. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. *Vaccine* **2000**; 18:2937-2944.
- Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA and Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. *Immunol.Rev.* **2006**; 211:236-254.
- Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ et al. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. *Int.J.Cancer* **2011**; 128:379-389.
- Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. *JAMA* **2007**; 298:743-753.
- Ho GY, Studentsov YY, Bierman R and Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. *Cancer Epidemiol.Biomarkers Prev.* **2004**; 13:110-116.
- Holowaty P, Miller AB, Rohan T and To T. Natural history of dysplasia of the uterine cervix. *J.Natl.Cancer Inst.* **1999**; 91:252-258.

- Höpfl R, Sandbichler M, Sepp N, Heim K, Muller-Holzner E, Wartusch B et al. Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia. *Lancet* **1991**; 337:373-374.
- Höpfl RM, Christensen ND, Angell MG and Kreider JW. Skin test to assess immunity against cottontail rabbit papillomavirus antigens in rabbits with progressing papillomas or after papilloma regression. *J.Invest Dermatol.* **1993**; 101:227-231.
- Höpfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. *Lancet* **2000**; 356:1985-1986.
- Hubert P, Caberg JH, Gilles C, Bousarghin L, Franzen-Detrooz E, Boniver J et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. *J.Pathol.* **2005**; 206:346-355.
- Huebner RE, Schein MF and Bass JB, Jr. The tuberculin skin test. *Clin.Infect.Dis.* **1993**; 17:968-975.
- Hung CF, Ma B, Monie A, Tsen SW and Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. *Expert.Opin.Biol.Ther.* **2008**; 8:421-439.
- Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. *Int.J.Cancer* **1996**; 66:162-169.
- Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, Adegbola RA et al. Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. *Int.J.Tuberc. Lung Dis.* **2006**; 10:192-198.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. *CA Cancer J.Clin.* **2011**; 61:69-90.
- Jenkins D, Sherlaw-Johnson C and Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? *Int.J.Cancer* **1996**; 65:768-773.
- Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. *Gynecol.Oncol.* **2008**; 110:S18-S25.
- Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? *Clin.Cancer Res.* **2008**; 14:2028-2035.
- Kalia V, Sarkar S, Gourley TS, Rouse BT and Ahmed R. Differentiation of memory B and T cells. *Curr. Opin.Immunol.* **2006**; 18:255-264.
- Kanodia S, Fahey LM and Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. *Curr.Cancer Drug Targets.* **2007**; 7:79-89.
- Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen GJ et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. *PLoS.One.* **2011**; 6:e17848.
- Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. *Sex Transm.Dis.* **1995**; 22:119-127.

- Kemp TJ, Hildesheim A, Safaiean M, Dauner JG, Pan Y, Porras C et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. *Vaccine* **2011**; 29:2011-2014.
- Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N.Engl.J.Med.* **2009**; 361:1838-1847.
- Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J.Natl.Cancer Inst.* **2005**; 97:1072-1079.
- Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. *BMJ* **2002**; 325:572.
- Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Res.* **2006**; 66:10630-10636.
- Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. *Cancer Prev.Res.(Phila)* **2009**; 2:868-878.
- Koutsky L. Epidemiology of genital human papillomavirus infection. *Am.J.Med.* **1997**; 102:3-8.
- Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. *Cancer Res.* **2006**; 66:10112-10119.
- Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. *J.Infect.Dis.* **2001**; 183:8-15.
- Maitland NJ, Conway S, Wilkinson NS, Ramsdale J, Morris JR, Sanders CM et al. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. *J.Pathol.* **1998**; 186:275-280.
- Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO and Keep SL. Surgery for cervical intraepithelial neoplasia. *Cochrane.Database.Syst.Rev.* **2010**;CD001318.
- Matloubian M, Concepcion RJ and Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. *J.Virol.* **1994**; 68:8056-8063.
- McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. *Lancet Oncol.* **2008**; 9:425-434.
- Medzhitov R and Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. *Cell* **1997**; 91:295-298.
- Melief CJ and van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. *Nat.Rev.Cancer* **2008**; 8:351-360.

- Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. *Int.J.Cancer* **2007**; 121:1749-1755.
- Monnier-Benoit S, Mauny F, Riethmuller D, Guerrini JS, Capilna M, Felix S et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. *Gynecol.Oncol.* **2006**; 102:22-31.
- Moore RA, Walcott S, White KL, Anderson DM, Jain S, Lloyd A et al. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. *Virology* **2003**; 314:630-635.
- Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. *JAMA* **2001**; 285:2995-3002.
- Moscicki AB, Schiffman M, Kjaer S and Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. *Vaccine* **2006**; 24 Suppl 3:S3-42-S3/51.
- Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N.Engl.J.Med.* **2003**; 348:518-527.
- Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. *Int.J.Cancer* **2004**; 111:278-285.
- Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J.Natl.Cancer Inst.* **2010**; 102:325-339.
- Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. *J.Infect.Dis.* **1997**; 175:927-931.
- Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. *J.Infect.Dis.* **2000**; 182:595-598.
- Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? *Int.J.Cancer* **2009**; 125:362-366.
- Nicolas JF and Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. *Expert.Rev.Vaccines.* **2008**; 7:1201-1214.
- Oosterhuis K, van den Berg JH, Schumacher TN and Haanen JB. DNA vaccines and intradermal vaccination by DNA tattooing. *Curr.Top.Microbiol.Immunol.* **2012**; 351:221-250.
- Ozsaran AA, Ates T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. *Eur.J.Gynaecol.Oncol.* **1999**; 20:127-130.
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* **2009**; 374:301-314.


- Palefsky JM, Gillison ML and Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. *Vaccine* **2006**; 24 Suppl 3:S3-140-S3/146.
- Palmroth J, Namujju P, Simen-Kapeu A, Kataja V, Surcel HM, Tuppurainen M et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. *Scand.J.Infect.Dis.* **2010**; 42:379-384.
- Parkin DM and Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine* **2006**; 24 Suppl 3:S3-11-S3/25.
- Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. *Cancer Res.* **2007**; 67:354-361.
- Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. *Int.J.Cancer* **2008**; 122:486-494.
- Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *J.Infect.Dis.* **2003**; 188:327-338.
- Plummer M, Schiffman M, Castle PE, Maucort-Boulch D and Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. *J.Infect.Dis.* **2007**; 195:1582-1589.
- Poulter LW, Seymour GJ, Duke O, Janossy G and Panayi G. Immunohistological analysis of delayed-type hypersensitivity in man. *Cell Immunol.* **1982**; 74:358-369.
- Pretorius RG, Peterson P, Azizi F and Burchette RJ. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. *Am.J.Obstet.Gynecol.* **2006**; 195:1260-1265.
- Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. *Int.J.Cancer* **1995**; 61:306-311.
- Rieser C, Ramoner R, Holtl L, Rogatsch H, Papesh C, Stenzl A et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. *Urol. Int.* **1999**; 63:151-159.
- Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. *J.Natl.Cancer Inst.* **2008**; 100:513-517.
- Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. *Vaccine* **2009**; 27:5612-5619.
- Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. *Br.J.Cancer* **2008**; 98:1704-1709.
- Sarkar AK, Tortolero-Luna G, Follen M and Sastry KJ. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. *Gynecol.Oncol.* **2005**; 99:S251-S261.

- Schiffman M and Castle PE. The promise of global cervical-cancer prevention. *N.Engl.J.Med.* **2005a**; 353:2101-2104.
- Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC et al. The carcinogenicity of human papillomavirus types reflects viral evolution. *Virology* **2005b**; 337:76-84.
- Selvakumar R, Borenstein LA, Lin YL, Ahmed R and Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. *J.Virol.* **1995**; 69:602-605.
- Seresini S, Origoni M, Lillo F, Caputo L, Paganoni AM, Vantini S et al. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. *J.Immunol.* **2007**; 179:7176-7183.
- Sherman ME. Chapter 11: Future directions in cervical pathology. *J.Natl.Cancer Inst.Monogr* **2003**;72-79.
- Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. *Hum.Vaccin.* **2007a**; 3:109-115.
- Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int.J.Cancer* **2007b**; 121:621-632.
- Smyth LJ, van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. *Clin.Cancer Res.* **2004**; 10:2954-2961.
- Snijders PJ, Steenbergen RD, Heideman DA and Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. *J.Pathol.* **2006**; 208:152-164.
- Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* **2002**; 287:2114-2119.
- Stanley M, Lowy DR and Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. *Vaccine* **2006a**; 24 Suppl 3:S3-106-S3/113.
- Stanley, M. Immunobiology of papillomaviruses. In: M.Saveria Campo, *Papillomavirus research: from natural history to vaccines and beyond* (first ed.). Caister Academic Press **2006b**; 311-320.
- Stanley M. Pathology and epidemiology of HPV infection in females. *Gynecol.Oncol.* **2010**; 117:S5-10.
- Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth MG et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. *Br.J.Cancer* **2005**; 93:248-259.
- Stetson CL, Rapini RP, Tyring SK and Kimbrough RC. CD4+ T lymphocytopenia with disseminated HPV. *J.Cutan.Pathol.* **2002**; 29:502-505.
- Stevenson M, Hudson LC, Burns JE, Stewart RL, Wells M and Maitland NJ. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. *J.Gen.Virol.* **2000**; 81:1825-1832.
- Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ and Wright TC, Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. *N.Engl.J.Med.* **1997**; 337:1343-1349.

- Terlou A, van SM, Kleinjan A, Heijmans-Antonissen C, Santegoets LA, Beckmann I et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. *Int.J.Cancer* **2010**; 127:2831-2840.
- Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. *Int.J.Cancer* **2006**; 119:2428-2434.
- Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE et al. Concurrent and sequential acquisition of different genital human papillomavirus types. *J.Infect.Dis.* **2000**; 182:1097-1102.
- Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. *Clin.Cancer Res.* **2005**; 11:4717-4723.
- Trimble CL, Peng S, Thoburn C, Kos F and Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. *Cancer Immunol.Immunother.* **2010a**; 59:799-803.
- Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. *J.Immunol.* **2010b**; 185:7107-7114.
- Trottier H and Franco EL. The epidemiology of genital human papillomavirus infection. *Vaccine* **2006**; 24 Suppl 1:S1-15.
- Turk JL. *Delayed hypersensitivity* (2nd ed.). Amsterdam: Elsevier, **1975**.
- Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. *Vaccine* **2005**; 23:5271-5280.
- van den Hende M, van Poelgeest MI, van der Hulst JM, de JJ, Drijfhout JW, Fleuren GJ et al. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. *Int.J.Cancer* **2008**; 123:146-152.
- van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J et al. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. *J.Infect.Dis.* **2010**; 202:1200-1211.
- van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E et al. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. *J.Immunol.* **1999**; 162:152-160.
- van der Burg SH, Rensing ME, Kwappenberg KM, de JA, Straathof K, de JJ et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. *Int.J.Cancer* **2001**; 91:612-618.
- van der Burg SH, Piersma SJ, de JA, van der Hulst JM, Kwappenberg KM, van den Hende M et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. *Proc.Natl.Acad.Sci.U.S.A* **2007**; 104:12087-12092.

- van Poelgeest MI, van SM, van BM, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. *Clin.Cancer Res.* **2005**; 11:5273-5280.
- van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter DJ, Fleuren GJ et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. *Int.J.Cancer* **2006**; 118:675-683.
- Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. *Vaccine* **2006**; 24:5571-5583.
- Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH and Akbar AN. Mantoux Test as a model for a secondary immune response in humans. *Immunol.Lett.* **2006**; 107:93-101.
- Wagstaff AJ and Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. *Drugs* **2007**; 67:2187-2210.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J.Pathol.* **1999**; 189:12-19.
- Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N.Engl.J.Med.* **1995**; 333:1038-1044.
- Wang S, Fan Y, Brunham RC and Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. *Eur.J.Immunol.* **1999**; 29:3782-3792.
- Wang X, Moscicki AB, Tsang L, Brockman A and Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. *Clin.Vaccine Immunol.* **2008**; 15:937-945.
- Welters MJ, de JA, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. *Cancer Res.* **2003**; 63:636-641.
- Welters MJ, van der Logt P, van den Eeden SJ, Kwappenberg KM, Drijfhout JW, Fleuren GJ et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. *Int.J.Cancer* **2006**; 118:950-956.
- Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin.Cancer Res.* **2008**; 14:178-187.
- Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. *Proc.Natl.Acad.Sci.U.S.A* **2010**; 107:11895-11899.
- Werkgroep Oncologische Gynaecologie. Richtlijn Cervicale Intra-epitheliale Neoplasie. **2004**.
- Wheeler CM, Hunt WC, Schiffman M and Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. *J.Infect.Dis.* **2006**; 194:1291-1299.
- Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. *Obstet.Gynecol.Clin.North Am.* **2008**; 35:519-536.


- Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. *J.Infect.Dis.* **2009**; 199:936-944.
- WHO/ICO information Centre on HPV and Cervical Cancer (HPV information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. <http://www.who.int/hpvcentre>. Accessed march **2011**.
- Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM et al. Development and duration of human papillomavirus lesions, after initial infection. *J.Infect.Dis.* **2005**; 191:731-738.
- Woo YL, Damay I, Stanley M, Crawford R and Sterling J. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens. *J.Virol.Methods* **2007**; 142:226-230.
- Woo YL, Sterling J, Damay I, Coleman N, Crawford R, van der Burg SH et al. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. *BJOG.* **2008**; 115:1616-1621.
- Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, Kwappenberg KM et al. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. *Int.J.Cancer* **2010**; 126:133-141.
- Woodfolk JA and Platts-Mills TA. Diversity of the human allergen-specific T cell repertoire associated with distinct skin test reactions: delayed-type hypersensitivity-associated major epitopes induce Th1- and Th2-dominated responses. *J.Immunol.* **2001**; 167:5412-5419.
- Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. *Lancet* **2001**; 357:1831-1836.
- Woodman CB, Collins SI and Young LS. The natural history of cervical HPV infection: unresolved issues. *Nat.Rev.Cancer* **2007**; 7:11-22.
- Woodworth CD. HPV innate immunity. *Front Biosci.* **2002**; 7:d2058-d2071.
- Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *Am.J.Obstet.Gynecol.* **2007**; 197:346-355.
- Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. *Cancer Res.* **2000**; 60:365-371.
- Zajac AJ, Murali-Krishna K, Blattman JN and Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. *Curr.Opin.Immunol.* **1998**; 10:444-449.
- zur Hausen H. Papillomavirus infections--a major cause of human cancers. *Biochim.Biophys.Acta* **1996**; 1288:F55-F78.
- zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. *Nat.Rev.Cancer* **2002**; 2:342-350.



Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

APC	antigen-presenting cell
ASCUS	atypical squamous cells of undetermined significance
CBA	cytometric bead array
CCL	chemokine ligands
CIN	cervical intraepithelial neoplasia
COPV	canine oral papilloma virus
CRPV	cotton tail rabbit papilloma virus
CTL	CD8 ⁺ cytotoxic T lymphocyte
DC	dendritic cell
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
DTH	delayed-type hypersensitivity
ELISA	enzyme-linked immunosorbent assay
ELISPOT	enzyme-linked immunospot assay
FCS	fetal calf serum
FR	frequency of responders
HBV	hepatitis B virus
hc2	hybrid capture 2 assay
HIV	human immunodeficiency virus
HLA	human leukocyte antigen
HPV	human papillomavirus
hrHPV	high-risk human papillomavirus
HSIL	high-grade squamous intraepithelial lesions
ICS	intracellular cytokine staining
IFN	interferon
Ig	immunoglobulin
IL	interleukin
IMDM	Iscove's Modified Dulbecco's Media
KC	keratinocytes

LA	linear array
LC	Langerhans cell
LEEP	loop electrosurgical excision procedure
LSIL	low-grade squamous intraepithelial lesions
LUMC	Leiden University Medical Center
MACS	magnetic cell sorting
MAdCAM	mucosal addressin cell adhesion molecule
MDA5	melanoma differentiation-associated gene 5
MRM	memory response mix
NF-κB	Nuclear Factor-KappaB
NTP	nucleotide triphosphate
PBMC	peripheral blood mononuclear cells
PCR	polymerase chain reaction
PHA	phytohemagglutinine
PKR	protein kinase R
PRR	pattern recognition receptor
RIG-I	retinoic-acid-inducible gene I
RUL	relative light unit
SI	stimulation index
SIL	squamous intraepithelial lesion
SLP	synthetic long overlapping peptides
TCGF	T cell growth factor
Th cell	CD4 ⁺ T helper cell
TLR	toll like receptor
TNF	tumor necrosis factor
Treg	CD4 ⁺ regulatory T cell
VIA	visual inspection with acetic acid
VIN	vulvar intraepithelial neoplasia
VLP	virus-like particles



Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands:

Sjoerd H. van der Burg, Jeanette M. van der Hulst, Joan de Jong and Kitty M.C. Kwappenberg.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands:

Lorraine M. Fathers, Jaap Oostendorp, Gijs Slappendel, A. Rob P.M. Valentijn and Amon R. Wafelman.

Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands:

Muriel van den Hende, Mariëtte I.E. van Poelgeest and Gemma G. Kenter.

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands:

Jan W. Drijfhout, Kees L.M.C. Franken, Cornelis J.M. Melief, Rienk Offringa, Anke Redeker and Marij J.P. Welters.

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands:

Gert Jan Fleuren.

Gertrude H. Sergievsky Centre, Department of Epidemiology, Columbia University School of Medicine, New York, USA:

Louise Kuhn

Department of Pathology, Columbia University School of Medicine, New York, USA:

Thomas C. Wright jr.

Department of Obstetrics and Gynecology, University of Cape Town, Cape Town, South Africa:

Rosalind Boa and Lynette Denny.

Center for Health Decision Science, Harvard School of Public Health, Boston, USA:

Sue J. Goldie.

Medical Research Council Cancer Cell Unit, University of Cambridge, Cambridge, UK:

Nicolas Coleman.

Department of Gynecology Oncology, Addenbrooke's Hospital, Cambridge, UK:

Robin A.F. Crawford and Yin Ling Woo.

Department of Pathology, Cambridge University, Cambridge, UK:

Margaret A. Stanley and Jane C. Sterling.



Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, **van den Hende M**, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. *Proc Natl Acad Sci U S A*. 2007;104:12087-92.

van den Hende M*, van Poelgeest MI*, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, Kenter GG. Skin reactions to Human Papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. *Int J Cancer* 2008;123:146-52.

Woo YL*, **van den Hende M***, Sterling S, Coleman N, Crawford RA, Kwappenberg KM, Stanley M, van der Burg SH. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. *Int J Cancer* 2010;126:133-41.


van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J, Valentijn AR, Fayers LM, Welters MJ, Melief CJ, Kenter GG, van der Burg SH, Offringa R. Evaluation of immunological cross-reactivity between clade A9 HR-HPV-types on basis of E6-specific CD4+ memory T-cell responses. *J Infect Dis*. 2010;202:1200-11.

Scholten KB, Turksma AW, Ruizendaal JJ, **van den Hende M**, van der Burg SH, Heemskerk MH, Meijer CJ, Hooijberg E. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. *J Transl Med*. 2011;9:147.

van den Hende M, Boa R, Redeker A, Kwappenberg KM, Kuhn L, Goldie SJ, Denny L, van der Burg SH, Wright TC, Offringa R. Evaluation of HPV E6-specific T-cell immunity in Haitian and South African women in relation to clearance or persistence of cervical HPV infections. *Submitted*.

van den Berg – van de Glind GJ, de Vries JJ, Wolthers KC, Wiggers – de Bruine FT, Peeters – Scholte CM, **van den Hende M**, van Wezel – Meijler G. Neonatal echovirus 6 meningo-encephalitis: a fatal course. *Submitted*.

* authors contributed equally




Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

Muriel van den Hende was born on the 6th of July, 1976 in Leidschendam. She attended the gymnasium at the Erasmus College in Zoetermeer, which she finished in 1994.

From 1994 to 2000 she studied Medicine and Biomedical Sciences at the University of Leiden. A graduation project at the department of Ophthalmology resulted in her first immunologic research project at the Schepens Eye Research Institute, Harvard Medical School in Boston. Where she studied MHC class II expression in uveal melanoma under supervision of S.J. Ono, MD, PhD and Dr. M.J. Jager (dept. of Ophthalmology, LUMC).

After obtaining her Medical Degree cum laude in November 2002, she worked as a resident at the Gynecology department of the Bronovo Hospital in The Hague (Dr. R.A. Verweij). In April 2004 she was appointed as a PhD student at the departments of Gynecology (Prof. Dr. G.G. Kenter) and Immunohematology & Blood transfusion, later Clinical Oncology (Prof. Dr. R. Offinga and Prof. Dr. S.H. van der Burg) of the Leiden University Medical Center, resulting in this thesis.

In October 2007 she started her residency training in Obstetrics and Gynecology at the Bronovo Hospital (Dr. C.A.G. Holleboom) and Leiden University Medical Center (Prof. Dr. J.J.L. van Lith) which she hopes to finish in August 2013.



Literature
Abbreviations
Authors and affiliations
Publications
About the author
Acknowledgments

Promoveren doe je niet alleen!

Graag wil ik alle patiënten en gezonde vrijwilligers, collega's van het lab Tumorimmunologie en Klinische Oncologie, arts-assistenten en gynaecologen in het LUMC en Bronovo, maar met name mijn vrienden, familie en in het bijzonder Arjan, Ivar en Reijer bedanken voor alle onvoorwaardelijke steun bij het schrijven en tot stand komen van dit proefschrift.

